PDCD1 and B-cell non-Hodgkin lymphoma: Undoubtedly, we have witnessed the impressive impact of anti-PD1 ICIs on outcomes of patients with r/r cHL and PMBCL which has encouraged clinical investigators to pursue clinical trials in many other subtypes of B-cell NHL.